Eighth and most interestingly, the downregulation of PDL‐1 within IDH‐mutant gliomas, which could be directly responsible for the resistance of IDH‐mutant gliomas to Nivolumab, including PMMRDIA. The gene discussed is IDH1; the disease is central nervous system cancer.